These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34870790)

  • 1. Abuse-Deterrent Opioids: A Survey of Physician Beliefs, Behaviors, and Psychology.
    Dasgupta N; Brown JR; Nocera M; Lazard A; Slavova S; Freeman PR
    Pain Ther; 2022 Mar; 11(1):133-151. PubMed ID: 34870790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Kentucky pharmacists' experiences in dispensing abuse-deterrent opioid analgesics.
    Oyler DR; Slavova S; Brown JR; Dasgupta N; Freeman PR
    J Am Pharm Assoc (2003); 2022; 62(6):1836-1842. PubMed ID: 36031547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abuse-deterrent opioids: an update on current approaches and considerations.
    Pergolizzi JV; Raffa RB; Taylor R; Vacalis S
    Curr Med Res Opin; 2018 Apr; 34(4):711-723. PubMed ID: 29262730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Abuse Deterrent Formulations of Opioids in Patients With Chronic Pain in the United States: A Cost-Effectiveness Model.
    Kumar VM; Agboola F; Synnott PG; Segel C; Webb M; Ollendorf DA; Banken R; Chapman RH
    Value Health; 2019 Apr; 22(4):416-422. PubMed ID: 30975392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Challenges Involved in the Development and Delivery of Abuse-deterrent Formulations of Opioid Analgesics.
    Cohen JP; Mendoza M; Roland C
    Clin Ther; 2018 Feb; 40(2):334-344. PubMed ID: 29398162
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An overview of abuse-deterrent opioids and recommendations for practical patient care.
    Adler JA; Mallick-Searle T
    J Multidiscip Healthc; 2018; 11():323-332. PubMed ID: 30026658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
    Cicero TJ; Ellis MS
    JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in drug use patterns reported on the web after the introduction of ADF OxyContin: findings from the Researched Abuse, Diversion, and Addiction-Related Surveillance (RADARS) System Web Monitoring Program.
    Vosburg SK; Haynes C; Besharat A; Green JL
    Pharmacoepidemiol Drug Saf; 2017 Sep; 26(9):1044-1052. PubMed ID: 28653782
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitigation of IV Abuse Through the Use of Abuse-Deterrent Opioid Formulations: An Overview of Current Technologies.
    Rauck RL
    Pain Pract; 2019 Apr; 19(4):443-454. PubMed ID: 30597739
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abuse-Deterrent Opioid Formulations: A Key Ingredient in the Recipe to Prevent Opioid Disasters?
    Salwan AJ; Hagemeier NE; Harirforoosh S
    Clin Drug Investig; 2018 Jul; 38(7):573-577. PubMed ID: 29651781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A tale of 2 ADFs: differences in the effectiveness of abuse-deterrent formulations of oxymorphone and oxycodone extended-release drugs.
    Cicero TJ; Ellis MS; Kasper ZA
    Pain; 2016 Jun; 157(6):1232-1238. PubMed ID: 27186712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current Impact and Application of Abuse-Deterrent Opioid Formulations in Clinical Practice.
    Lee YH; Brown DL; Chen HY
    Pain Physician; 2017 Nov; 20(7):E1003-E1023. PubMed ID: 29149148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Trends in Abuse-Deterrent Formulations: Technological Insights and Regulatory Considerations.
    Rana D; Salave S; Benival D
    Curr Drug Deliv; 2022; 19(8):846-859. PubMed ID: 34879799
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Primary Care Physicians' Knowledge and Attitudes Regarding Prescription Opioid Abuse and Diversion.
    Hwang CS; Turner LW; Kruszewski SP; Kolodny A; Alexander GC
    Clin J Pain; 2016 Apr; 32(4):279-84. PubMed ID: 26102320
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting.
    Peacock A; Larance B; Bruno R; Pearson SA; Buckley NA; Farrell M; Degenhardt L
    Addiction; 2019 Mar; 114(3):389-399. PubMed ID: 29989247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and impact of prescription opioid abuse deterrent formulation technologies.
    Alexander L; Mannion RO; Weingarten B; Fanelli RJ; Stiles GL
    Drug Alcohol Depend; 2014 May; 138():1-6. PubMed ID: 24613631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current and future development of extended-release, abuse-deterrent opioid formulations in the United States.
    Webster LR; Markman J; Cone EJ; Niebler G
    Postgrad Med; 2017 Jan; 129(1):102-110. PubMed ID: 27915497
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in Abuse-Deterrent Formulation Opioid Prescribing in California, Florida, and Kentucky in 2018.
    Brown JR; Oh G; Wang Y; Slavova S; Delcher C; Dasgupta N; Freeman PR
    J Rural Health; 2021 Jan; 37(1):23-28. PubMed ID: 32686223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Application of Hot Melt Extrusion Technology in the Development of Abuse-Deterrent Formulations: An Overview.
    Butreddy A; Nyavanandi D; Narala S; Austin F; Bandari S
    Curr Drug Deliv; 2021; 18(1):4-18. PubMed ID: 32811398
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What's holding back abuse-deterrent opioid formulations? Considering 12 U.S. stakeholders.
    Pergolizzi JV; Taylor R; LeQuang JA; Raffa RB
    Expert Opin Drug Deliv; 2018 Jun; 15(6):567-576. PubMed ID: 29739241
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.